Abstract Mutations in the Aristaless-related homeobox gene (ARX) are associated with a wide variety of neurologic disorders including lissencephaly, hydrocephaly, West syndrome, Partington syndrome, and X-linked intellectual disability with or without epilepsy. A genotype-phenotype correlation exists for ARX mutations; however, the molecular basis for this association has not been investigated. To begin understanding the molecular basis for ARX mutations, we tested the DNA binding sequence preference and transcriptional repression activity for Arx, deletion mutants and mutants associated with various neurologic disorders. We found DNA binding preferences of Arx are influenced by the amino acid sequences adjacent to the homeodomain. Mutations in the homeodomain show a loss of DNA binding activity, while the T333N and P353R homeodomain mutants still possess DNA binding activities, although less than the wild type. Transcription repression activity, the primary function of ARX, is reduced in all mutants except the L343Q, which has no DNA binding activity and does not functionally repress Arx targets. These data indicate that mutations in the homeodomain result in not only a loss of DNA binding activity but also loss of transcriptional repression activity. Our results provide novel insights into the pathogenesis of ARX-related disorders and possible directions to pursue potential therapeutic interventions.
Introduction
Mutations in the Aristaless-related homeobox gene (ARX) are identified in a broad spectrum of neurocognitive disorders. Patient phenotypes range from severe structural anomalies of the brain such as lissencephaly to structurally normal-appearing brains with intellectual disabilities [1, 2] . Mutations in ARX have been associated with a variety of developmental processes including proliferation of neocortical neuronal progenitors, neuronal differentiation, and migration of interneurons [3] [4] [5] [6] [7] [8] [9] [10] . These cellular defects are believed to underlie the various structural and functional phenotypes observed in the patients.
ARX is a transcription factor with a paired-like homeodomain in addition to an octapeptide domain, four polyalanine tracts, three NLS, an acidic domain, and an Aristaless domain [11] [12] [13] . It is expressed in the ventricular zone of the developing neocortex, the source of cortical excitatory neurons, and in the ganglionic eminence where cortical interneurons are derived [6, [14] [15] [16] . Existing data suggest Arx controls neocortical ventricular zone cell proliferation and both radial and nonradial neuronal migration [8, 9] . In addition, Arx has identified roles in olfactory bulb and pancreas development [17, 18] . Both in vitro and in vivo studies have determined that Arx primarily functions as a transcriptional repressor, but that it can also act as an activator [5, 12, 13, [18] [19] [20] .
The homeodomain is composed of 60 highly conserved amino acids forming three alpha helices, which interact with the minor and major groove of the core sequence "TAAT" [21, 22] . In addition to the alpha helices, homeodomain proteins possess an N-terminal arm that confers the DNA binding sequence specificity. Cooperative interaction with cofactors, including other homeodomain proteins, contributes to the DNA binding specificity for development-related gene regulation [23] [24] [25] [26] .
Pathogenic mutations in ARX have been found in multiple regions of the coding sequence, and correlations have been made between genotype and phenotype [1, 2] . Among the mutations identified in ARX are (1) Expansion in the first or second polyalanine tract, (2) frameshift mutations resulting in a truncated protein, (3) deletions, and (4) point mutations within and outside of the homeodomain. The mutations in the homeodomain allegedly disrupt DNA binding, although whether such point mutations prevent binding or result in binding off-target DNA sequences has not been well characterized.
In this study, we investigated the DNA binding sites of Arx and tested the ability of several known human disease-associated point mutations and deletion mutants to bind the canonical ARX DNA binding sequence. Furthermore, we determined whether these known point mutations, associated with human disease, maintained transcriptional repression activity. Our data provide novel insight into the functional defects associated with these human disease-associated mutations.
Methods and materials

Plasmids and generation of mutants
Full-length Arx was amplified by PCR using ArxF-E (5′-CGGAATTCCACCATGAGCAATCAGTACCAGGAA GAGGGC-3′) and ArxR-MluI (5′-ACTTCAACGCGTCTA CAGATCTTCTTCAGAAATAAGTTTTTGTTCGCA-3′), and the product was cloned into the EcoRI and MluI sites of pCAG-IRES-EGFP. The pM-Arx constructs containing the Gal4 DNA binding domain were generated by PCR using primers ArxF-E and ArxR-Xb (5′-TGCTCTAGATTAGCA CACCTCCTTCCCCGTGCTG-3′). The pTYB2-Sumo-Arx was constructed by cloning the amplified DNA fragment containing human SUMO and mouse Arx into pTYB2 (NEB). Sequences corresponding to amino acids 214-430, 286-430 of Arx were amplified by PCR using primers 286F-E (5′-CGGAATTCGAGAGGGCGGGGAGCTGTCGCC-3′) and 430R-Xh (5′-CCGCTCGAGTTACGAATCAAGCG CAGGGTGATGCG-3′), digested with EcoRI and XhoI and then cloned into the EcoRI and XhoI sites of pGEX-5X-3 (Amersham Biosciences) or pET28a (Novagen; Fig. 1a ). Point mutations were introduced by a common PCR mutagenesis protocol. The mouse sequence of Arx was used in all the experiments, although the mutants were based on the human sequence number to preclude confusing amino acid residues number; mouse Arx is one amino acid shorter than human ARX in the homeodomain region.
Protein purification
Glutathione-S-transferase (GST)-Arx and His-Arx fusion proteins along with SUMO-tagged Arx were expressed in BL21 competent cells (Invitrogen) with expression induced by the addition of 0.3 mM IPTG to late logarithmic cultures (OD=0.5) for 3 h at 27°C. Cells were then harvested, resuspended in phosphate-buffered saline (PBS), pH 7.4, containing 0.5% triton X-100, and disrupted by sonication in the presence of a protease inhibitor cocktail (Sigma). After centrifugation, the supernatants were applied to glutathione-Sepharose beads (Amersham Bioscience), nickel-nitrilotriacetic acid (Ni-NTA) beads (Qiagen), and chitin bead (NEB), respectively. The glutathione and Ni-NTA beads were washed with PBS, while column buffer (20 mM MES-HCl, pH 6.5, 500 mM NaCl) was used for the chitin bead. Each fusion protein was eluted according to the manufacturer's instructions. The GST fusion protein was finally eluted with 30 mM glutathione in 100 mM Tris-Cl, pH 7.4. The His fusion protein was eluted with 250 mM imidazole containing PBS and the Sumo fusion protein with 10 mM dithiothreitol (DTT).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assays (EMSA) were performed as previously described with slight modifications [19] . Oligonucleotides (5 pmol) were labeled by T4 polynucleotide kinase in the presence of [γ-32P] ATP (6,000 Ci/mmol; Amersham Bioscience). Unincorporated [γ-32P] ATP was removed by column filtration using MicroSpin G-25 columns (Amersham Biosciences). The purified probe was annealed in Buffer H (Roche) by heating for 1 min and cooling to room temperature. One hundred nanograms of GST-Arx derivatives was incubated with 0.025 pmol of labeled probe in total 20 μl of binding buffer [20 mM HEPES, pH 7.4, 50 mM KCl, 1 mM MgCl 2 , 1 mM DTT, 5% glycerol, 0.05% Triton X-100, and 1 μg poly(dI-dC) (Roche)] for 30 min on ice. The mixture was loaded on a 5% polyacrylamide gel and electrophoresed (constant 33 mA) at 4°C in 1× TBE. Gels were dried and visualized on a phosphorimager (Molecular Dynamics). The oligonucleotides used were as follows: Lmo1: 5′-GTAAT GAATTGATTTAATTAACAGGGGAGTCTGA-3′, N11 (5′-GTCTGGCAGTTAATTCGGCTTAGTAGC-3′), N30 (5′-GTCTGGCCTCTAATTACGCCTAATTGC-3′), N9 (5′-GTCTGGCTCCTAATTAGTTCGATTAGC-3′), N26 (5′-GTCTGGCCTCTAATTACGCCTAATTGC-3′), N2 (5′-GTCTGGCAATTAATATATTGCATTTGC-3′), and N25 (5′-GTCTGGCCATTAATGATATCAATTAGC-3′).
Cell culture, transfection, and reporter assay HEK293T cells were transfected 24 h after plating with 200 ng of luciferase reporter plasmid DNA, 50 ng of pMArx or mutants, and 50 ng of pRL-TK Renilla luciferase plasmid DNA (Promega) using FuGENE 6 (Roche Diagnostics, Alameda, CA). Forty-eight hours posttransfection, cell lysis and measurement of firefly and Renilla luciferase activity were performed using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instruction using a Veritus Microplate Luminometer (Turner BioSystems, Sunnyvale, CA). Transfections were performed in quadruplicate and replicated in three independent experiments. The firefly luciferase activity was normalized according to the corresponding Renilla luciferase activity, and luciferase activity was reported as relative mean (±SD). SELEX Systematic Evolution of Ligands by EXponential enrichment (SELEX) was performed as previously described with several modifications [27] . The double-strand DNA containing the TAAT core sequences, random sequences, and primer binding sites was generated by PCR using the following template (5′-TAGGCATGTGGATCCGTCTGGCN 3 TAATN 11 GCG TACCGGATCCACCTTCGAT-3′) and PCR primers (5′-TAGGCATGTGGATCCGTCTGGC-3′ and 5′-ATC The arrowhead and arrow indicate the Arx-DNA complex and free probe, respectively. Sequence logo for Arx-DNA binding sites was generated by MEME GAAGGTGGATCCGGTACGC-3′). The products were purified using the PCR extraction kit (Qiagen). DNA-protein binding was performed at 4°C for 30 min in a reaction buffer (20 mMTris-HCl pH 7.2, 50 mM KCl, 1 mM EDTA, 1 mM DTT, 1 μg dIdC in 20 μl reaction, 0.05% Triton X-100, and 10% glycerol). After binding, the glutathione beads (Amersham) were added to the reaction. The beads were washed five times with the reaction buffer without dIdC. DNA was eluted with 10 mM glutathione-containing reaction buffer. The eluted DNA was cleaned with the PCR extraction kit (Qiagen). The cleaned DNA was amplified with the primers for 18 cycles (annealing temperature of 54°C for 30 s), and this amplified DNA was then used for panning. This procedure was performed six times. The enriched DNA was subcloned into pCR2.1 vector and sequenced.
Results and discussion
Arx can bind to 5′-T/cTAATT-3′
To determine the DNA binding site of Arx on naked DNA, we performed SELEX. As previously determined, Arx can bind to the TAAT core sequence found with most homeodomain proteins [19, 28] . To characterize the specificity, we designed an oligonucleotide containing the fixed core sequence (N3TAATN12; bold is core sequence) and tested the ability of the GST-Arx (286-430) protein containing the homeodomain (Fig. 1a) to bind. Panning was performed six times for the DNA fragments to bind the GST-Arx with glutathione beads, testing DNA binding activities after each panning (Fig. 1b) . The selected DNA sequence is the 5′-T/cTAATT-3′; the 5′ side of TAAT has T or C preference, while the 3′side of TAAT has a T preference (Fig. 1b) . These data indicate that Arx requires sequence information adjacent to the 5′-TAAT-3′ sequence for DNA binding.
DNA binding preferences of Arx are variable depending on protein structure
We postulated that the adjacent amino acid sequence information near homeodomain would determine Arx DNA binding preference. To test this, we performed EMSA with full-length Arx protein and several deletion mutants (Fig. 2) . The EMSA probes were selected from representatives found in the sequence pool determined by SELEX. We found that full-length Arx has a T/C/A preference on the 5′ end and T preference on the 3′ end of the TAAT core sequence (Fig. 2a and (Fig. 2b-c and Table 1 ). In contrast, the 286-430 protein showed strong DNA binding activity when fused to GST, but lost all binding activity when fused to His-tagged ( Fig. 2d-e and Table 1 ). Compared to full-length Arx, the 214-430 and 286-430 proteins lost their T preference on the 5′ side when T was at the position 3′ to the TAAT (Table 1) . On the other hand, both deletion mutants maintained a T preference on the 5′ side when the 3′ end was a G (Table 1) . GST and His tags have significant size differences; GST is 24 kD and His tag is 3 kD. We predicate that the GST fusion could introduce a significant conformational change, which could affect DNA binding affinity or preference. However, our result shows that DNA binding affinity or preference was not altered by the fusion ----N11  N11  N30  N9  N26  N2  N25  N11  N11  N30  N9  N26  N2  N25  N11  N11  N30  N9  N26  N2  N25  N11  N11  N30  N9  N26  N2  N25  N11  N11  N30  N9  N26  N2  N25 Table 1 . Arrowhead indicates the Arx/DNA complex protein size, but a combination of the specific deletion and fusion partner. Taken together, these data indicate that DNA binding preferences are diverse depending on protein structure influenced by both the fusion partner and the deletion. Furthermore, this implies that the Arx homeodomain's DNA binding preference could be influenced by its [32] . b MEME-based sequence logo from 84 homeodomains (Reprinted from Noyes et al. [33] , Copyright 2008, with permission from Elsevier) is compared to the mutation sites in human ARX. c DNA binding activities for human ARX mutants using the Lmo1 probes [19] . Arrowhead indicates the Arx-DNA complex. In these experiments, the GST-286-430 protein, which has 100% homology between the human and mouse, was used. d Transcriptional repression activity was tested with a Gal4-based luciferase assay. The R332H, R332P, and T333N mutants were statistically significant when compared to the wild type (p <0.05). The P353R mutant approached statistical significance (p=0.053). The L343q was not significantly different from the wild type (p>0.05). Y-axis indicates a relative luciferase activity interaction partners including other transcription factors or transcriptional co-activators/repressors. These data lead us to reconsider the sequence information from the transcription factor binding site database, which was generated by using only the DNA binding domain.
Analysis of DNA binding activity of Arx homeodomain mutants
Seven missense mutations, leading to a single amino acid substitution in the homeodomain of ARX, have been identified in patients with intellectual disabilities [1] . Six of these mutations are correlated with structural brain malformations. The R332C/R332H/R332P, L343Q, and P353R mutations are associated with X-linked lissencephaly with ambiguous genitalia (XLAG). In contrast, the T333N mutation is associated with agenesis of corpus collosum (Proud syndrome) [9, 29, 30] . Mutations at R332 or L343 are more severe than the T333 or P353 mutations [30] . One mutation, P353L, has a milder phenotype with no structural defects but seizures and intellectual disability; this mutant has an amino acid change between conserved amino acids in the homeodomain [31] . Thus, different homeodomain point mutations can result in very different phenotypes. To understand how such difference might result from mutations in the same functional domain, we introduced these mutations into mouse Arx and tested their DNA binding activity and transcription repression activity. The five missense mutations associated with XLAG were all in highly conserved amino acids (Fig. 3a, b) . This led us to hypothesize that all mutants have different DNA binding activity depending on the position. As expected, T333N and P353R bound DNA but with lower affinity than wildtype Arx (Fig. 3c) . These data are consistent with the DNA binding activities of mutants correlating with phenotype. Although we did not test the DNA binding activity for the P353L, we would predict this mutant would bind DNA, based on the sequence conservation at this position of the homeodomain.
Homeodomain mutants have loss of transcription repression activities
We previously identified Lmo1, Ebf3, and Shox2 as direct targets of Arx repression [19] . Given that some of the mutants have lost DNA binding activity (Fig. 3c) , it would be impossible to test their transcription repression activity on these genes. Therefore, we employed a Gal4-based reporter gene assay system. This system does not require the DNA binding domain of Arx; instead, it utilizes the Gal4 DNA binding domain. We designed the Gal4 fusion protein expression constructs for wild-type Arx or each point mutant. As shown in the previous report [13] , wildtype Gal4-Arx represses the activity of the Gal4 reporter. L343Q has a similar transcription repression activity to wild type. However, R332H, R332P, T333N, and P353R mutants have a reduced transcription repression activity (Fig. 3d) . Although T333N and P353R have similarly low DNA binding activities, our data suggest that the T333N has a more severe phenotype in patients because of reduced transcriptional repression. Taken together, our data suggest that the phenotypes associated with these mutations do not solely result from a loss of DNA binding activity but also the loss of transcription repressive activity.
In summary, we find that the DNA binding preferences of Arx and mutant forms of Arx are influenced by the evolutionally conserved amino acids in the homeodomain and its adjacent sequence information. Furthermore, we found that the phenotypic severity associated with Arx mutations is a result of both DNA binding activity and abrogation of transcriptional activity.
